Polyene Phosphatidylcholine

DRUG5 trials

Sponsors

AMIpharm Co., Ltd., General Hospital of Shenyang Military Region, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Drug Induced Liver InjuryDrug-Induced Liver InjuryHealthyHealthy SubjectsModerate or Severe Submental FullnessSubmental Fat

Phase 1

Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects

CompletedNCT05476094

AMIpharm Co., Ltd.Healthy Subjects, Submental Fat

Start: 2022-08-10End: 2023-08-23Updated: 2026-01-22

Phase 2

Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

CompletedNCT05266729

AMIpharm Co., Ltd.Moderate or Severe Submental Fullness

Start: 2022-03-02End: 2023-02-20Updated: 2023-08-15

Phase 3

Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area

CompletedNCT06256445

AMIpharm Co., Ltd.Healthy

Start: 2024-03-26End: 2025-10-30Updated: 2026-01-22

Unknown Phase

Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

RecruitingNCT06922669

General Hospital of Shenyang Military RegionDrug Induced Liver Injury

Start: 2025-06-24End: 2027-09-30Target: 232Updated: 2025-12-18

A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases

Not yet recruitingNCT07476885

Institute of Hematology & Blood Diseases Hospital, ChinaDrug-Induced Liver Injury

Start: 2026-03-31End: 2027-01-31Target: 1000Updated: 2026-03-17

Related Papers

Phase 1 study of AYP-101 (soybean phosphatidylcholine): safety, pharmacokinetics, and lipid profile effects for reducing submental fat.

2024-12-281 citations